股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 福森藥業有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01652 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 739,301,000 | | 0 | | 739,301,000 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 739,301,000 | | 0 | | 739,301,000 | 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港 ...

福森药业(01652.HK)：上半年股东应占亏损为2310万元 福森药业(01652.HK)将于8月29日召开董事会会 议以审批中期业绩 格隆汇8月29日丨福森药业(01652.HK)发布公告，2025年上半年，收益同比减少约43.3%至约人民币 1.133亿元；毛利同比下降约59.4%至约人民币4300万元；公司股权持有人应占亏损为约人民币2310万 元，而于2024年上半年则为亏损约人民币3690万元。 相关事件 ...

福森药业(01652)发布截至2025年6月30日止六个月的中期业绩，收益1.11亿元(人民币，下同)，同比减 少43.31%;股东应占亏损2313.6万元，同比收窄37.37%;每股基本亏损3分。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Fusen Pharmaceutical Company Limited 福森藥業有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 截 至2025年6月30日 止 六 個 月 的 中 期 業 績 公 告 福 森 藥 業 有 限 公 司（「本 公 司」）董 事 會（「董 事 會」）在 此 公 佈 本 公 司 及 其 附 屬 公 司 截 至2025年6月30日 止 六 個 月（「期 間」或「期 內」）之 未 經 審 核 中 期 業 績 連 同2024年 同 期 的 比 較 數 字。 財 經 摘 要 – 1 – — 收 益 由2024年 上 半 年 約 人 民 幣196.3百 萬 元 減 少 約43.3%至20 ...

格隆汇8月19日丨福森药业(01652.HK)公布，公司将于2025年8月29日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及宣派中期股息（如有）。 ...

Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1652） 董事會會議通告 福 森 藥 業 有 限 公 司（「 本 公 司 」）董 事 會（「 董 事 會 」）謹 此 宣 佈 ， 董 事 會 將 於 2025 年 8月29日（ 星期五 ）舉行會議，藉以（ 其中包括 ）考慮及批准本公司及其附屬公司截 至 2025 年6 月 30 日 止六 個 月之 未經 審 核中 期業 績及 其 發佈 ，以 及 考慮 宣派 中 期股 息（ 如有）。 承董事會命 福森藥業有限公司 主席兼執行董事 曹智銘 香港，2025年8月19日 於 本 公 告 日 期 ， 本 公 司 董 事 會 包 括 執 行 董 事 曹 智 銘 先 生（ 主 席 ）、 侯 太 生 先 ...

呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01652 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 福森藥業有限公司 本月底法定/註冊股本總額： HKD 20,000,00 ...

5月23日，截至港股收盘，恒生指数上涨0.24%，报23601.26点。福森药业（01652.HK）收报0.39港元/ 股，上涨30.0%，成交量430.9万股，成交额160.42万港元，振幅45.0%。 最近一个月来，福森药业累计涨幅11.11%，今年来累计跌幅62.5%，跑输恒生指数17.37%的涨幅。 财务数据显示，截至2024年12月31日，福森药业实现营业总收入3.26亿元，同比减少42.36%；归母净利 润-1.89亿元，同比减少420.39%；毛利率49.88%，资产负债率70.25%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 资料显示，福森药业有限公司除提供核心产品双黄连类感冒药外,福森药业有限公司从事研发、生产及 销售多种用以治疗感冒及发热、心血管疾病及贫血的中成药及西药产品。福森药业有限公司对优质非处 方药及按现代剂型调配的处方中成药产品拥有专门知识。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 本文源自：金融界 作者：行情君 行业估值方面，药品及生物科技行业市盈率（TTM）平均值为5.54倍，行业中值6倍。福森药业市盈 率-1.09倍， ...

Financial Performance - The company's revenue for 2024 was RMB 326.03 million, a significant decrease from RMB 565.61 million in 2023, representing a decline of approximately 42.3%[6]. - The gross profit for 2024 was RMB 162.64 million, down from RMB 299.51 million in 2023, indicating a decrease of about 45.5%[6]. - The company reported a net loss of RMB 188.80 million for 2024, compared to a loss of RMB 36.30 million in 2023, marking a significant increase in losses[6]. - Revenue decreased by approximately RMB 239.6 million or 42.4% to about RMB 326.0 million for the year ended December 31, 2024, down from approximately RMB 565.6 million in 2023[15]. - The company's gross profit for 2024 was approximately RMB 162.6 million, with a gross margin of about 49.9%, down from a gross profit of approximately RMB 299.5 million and a gross margin of 53.0% in 2023[17]. - The company reported a net loss of approximately RMB 188.8 million for the year ended December 31, 2024, representing a significant increase in loss of about 420.2% compared to the previous year[12]. Expenses and Liabilities - Research and development expenses reached RMB 106.26 million in 2024, which contributed to the overall loss for the year[9]. - The total liabilities increased to RMB 869.80 million in 2024, up from RMB 781.52 million in 2023, reflecting an increase of about 11.3%[7]. - Selling and distribution expenses decreased by approximately RMB 58.5 million or 42.0% to about RMB 81.0 million in 2024, compared to RMB 139.5 million in 2023[19]. - The company achieved a significant reduction in general and administrative expenses, which fell by approximately RMB 14.6 million or 19.5% to about RMB 60.3 million in 2024[20]. - Financing costs net increased to approximately RMB 18.8 million in 2024 from RMB 8.8 million in 2023, mainly due to increased interest on loans and foreign exchange losses[22]. Market and Future Outlook - Future market uncertainties remain the biggest challenge, but management aims to achieve profitability through refined management and quick adjustments[10]. - The company plans to enhance its product pipeline with new products pending approval, which could contribute to future revenue growth[9]. - The company expects to participate in national centralized procurement, with flagship products successfully winning bids, which is anticipated to drive significant sales growth in 2025[14]. Corporate Governance - The company has adopted the corporate governance code as per the listing rules, with some exceptions noted[68]. - The board of directors is responsible for overseeing the company's overall strategy and performance, including risk management and internal controls[71]. - The company has provided liability insurance for its directors and senior management to cover potential legal liabilities incurred during the performance of their duties[72]. - The independent non-executive directors have confirmed compliance with the non-competition agreement provided by the controlling shareholders[70]. - The company has established a comprehensive internal control system to monitor financial performance and risk management[72]. Environmental, Social, and Governance (ESG) Initiatives - The company emphasizes sustainable development and has implemented measures to reduce environmental impact, including energy-saving and emission-reduction initiatives[125]. - The company aims to create a green pharmaceutical enterprise, actively promoting clean production and pollution reduction to support national carbon neutrality goals[137]. - The company is focused on enhancing its ESG governance framework and internal controls to ensure scientific and rational decision-making[125]. - The company has established a comprehensive ESG governance structure, with the Audit Committee responsible for overseeing ESG reporting processes and risk management[135]. - The company is committed to enhancing product quality and safety, accelerating the development of innovative products, and strengthening quality control measures[145]. Climate Change and Risk Management - The company is facing physical risks from extreme weather affecting supply chains and production facilities, and is implementing strategies such as diversified procurement and facility reinforcement[150]. - The company is investing in new technologies and processes to adapt to extreme weather, including the development of resilient medicinal materials[148]. - The company has established a climate risk management process, identifying and analyzing climate-related risks annually within its governance structure[162]. - The company aims to reduce carbon emissions by 20% by 2025 compared to 2020 levels, with a target to decrease unit product energy consumption by 5% and increase green electricity procurement rate to 10%[165]. Employee and Stakeholder Engagement - The company emphasizes the importance of employee development and training, focusing on innovative drug research and optimizing the traditional Chinese medicine industry chain[140]. - The company has identified key stakeholders, including employees, consumers, suppliers, and investors, and has established multiple communication channels to address their concerns[142]. - The workforce composition is 50.91% female and 49.09% male, reflecting the company's commitment to gender diversity[97].

Revenue and Profitability - Revenue for the year ended December 31, 2024, was approximately RMB 326.0 million, a decrease of about 42.4% compared to RMB 565.6 million for the year ended December 31, 2023[2]. - Gross profit decreased by approximately 45.7% to RMB 162.6 million for the year ended December 31, 2024, down from RMB 299.5 million for the year ended December 31, 2023[2]. - The gross profit margin for the year ended December 31, 2024, was approximately 49.9%, a decrease of about 3.1% from approximately 53.0% for the year ended December 31, 2023[2]. - The loss attributable to equity holders for the year ended December 31, 2024, was approximately RMB 188.8 million, compared to a loss of RMB 36.3 million for the year ended December 31, 2023[2]. - Basic loss per share for the year ended December 31, 2024, was approximately RMB 0.26, compared to RMB 0.05 for the year ended December 31, 2023[2]. - The company reported a significant operating loss of RMB 188.8 million for 2024, attributed to a substantial decline in revenue due to market demand and intense competition[11]. - The group reported a net loss of approximately RMB 188.8 million for the year ending December 31, 2024, representing a significant increase in losses of about 420.2% compared to the previous year[38]. - The group's pre-tax loss was RMB 190,446,000 for 2024, compared to a loss of RMB 29,448,000 for 2023, reflecting a significant increase in losses[27]. Financial Position - The company's total assets amounted to RMB 778.5 million as of December 31, 2024, slightly up from RMB 776.9 million in 2023[6]. - The company's current liabilities increased to RMB 772.4 million in 2024 from RMB 664.5 million in 2023, indicating a rise in short-term financial obligations[6]. - The company’s total liabilities reached RMB 465.7 million in 2024, down from RMB 679.2 million in 2023, suggesting a reduction in overall debt levels[6]. - The company's total equity attributable to shareholders was RMB 465.7 million in 2024, a decrease from RMB 679.2 million in 2023, indicating a decline in shareholder value[6]. - The group's total liabilities amounted to approximately RMB 869.8 million as of December 31, 2024, an increase of 11.3% from RMB 781.5 million in 2023[60]. - The group's equity attributable to shareholders was approximately RMB 369.7 million as of December 31, 2024, down from RMB 563.5 million in 2023[53]. Cash Flow and Liquidity - The company’s cash and cash equivalents decreased to RMB 21.1 million in 2024 from RMB 34.8 million in 2023, showing a decline in liquidity[6]. - As of December 31, 2024, the company's net current liabilities amounted to RMB 312.83 million, with a commitment to repay bank loans and other borrowings totaling RMB 303.54 million within one year[11]. - The group’s current liabilities amounted to RMB 312.8 million, with a commitment to repay bank and other loans of RMB 303.5 million within one year[37]. - The company continues to adhere to a prudent cash management policy to maintain strong liquidity for future growth opportunities[59]. Expenses and Cost Management - Employee costs for the year ending December 31, 2024, were RMB 78,257,000, down from RMB 103,881,000 in 2023, reflecting a reduction of approximately 25%[21]. - The cost of goods sold for the year ending December 31, 2024, was RMB 164,227,000, compared to RMB 269,244,000 in 2023, showing a decrease of about 39%[23]. - Selling and distribution expenses decreased by approximately RMB 58.5 million or 42.0% to approximately RMB 81.0 million for the year ended December 31, 2024, in line with reduced revenue[46]. - Research and development expenses for 2024 were approximately RMB 106.3 million, an increase of RMB 41.1 million compared to 2023[39]. - The group experienced an operating loss of approximately RMB 67.5 million in 2024, compared to an operating profit of approximately RMB 20.0 million in 2023[39]. Taxation - The group reported a tax provision of RMB 9,194,000 for 2024, compared to RMB 12,725,000 for 2023, indicating a decrease of approximately 27.5%[24]. - The effective tax rate for the group's Chinese subsidiaries is 25% for both 2024 and 2023, while the Hong Kong profits tax rate remains at 16.5%[25]. - The group has no taxable profits in Hong Kong for 2024, consistent with 2023, and is not required to pay any Hong Kong profits tax[25]. - The group’s subsidiaries are set to maintain their high-tech enterprise status until October 28, 2027, and December 28, 2026, respectively, which will continue to provide tax benefits[25]. Shareholder Information - The board of directors does not recommend the payment of any final dividend for the year ended December 31, 2024 (no dividend for the year ended December 31, 2023)[2]. - The company has issued 739,301,000 ordinary shares as of December 31, 2024, down from 749,596,000 shares in 2023[34]. - The company repurchased a total of 5,734,000 shares at a total cost of approximately HKD 7.1 million, which were all cancelled by December 31, 2024[70]. - The repurchase was authorized by shareholders to enhance net asset value and earnings per share, benefiting shareholders overall[71]. Future Outlook and Strategy - The company plans to enhance sales efforts, including accelerating the sale of existing inventory and implementing stricter cost control measures to improve operational cash flow[15]. - The group anticipates that participation in national centralized procurement will drive significant sales growth in 2025[41]. - The group plans to optimize its R&D project plans and control R&D expenses within reasonable limits for future sustainability[41]. Corporate Governance - The company has adopted corporate governance practices in compliance with the listing rules, with a focus on maintaining effective oversight and management[66]. - The independent auditor's report confirms that the consolidated financial statements reflect the group's financial position as of December 31, 2024, in accordance with international financial reporting standards[36].